
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">JMM Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">JMM Case Rep</journal-id><journal-id journal-id-type="publisher-id">JMMCR</journal-id><journal-title-group><journal-title>JMM Case Reports</journal-title></journal-title-group><issn pub-type="epub">2053-3721</issn><publisher><publisher-name>Microbiology Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28348775</article-id><article-id pub-id-type="pmc">5330243</article-id><article-id pub-id-type="publisher-id">jmmcr005053</article-id><article-id pub-id-type="doi">10.1099/jmmcr.0.005053</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Central Nervous System</subject><subj-group><subject>Opportunistic Infections</subject><subject>Viruses</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia</article-title><alt-title alt-title-type="recto-page-foot"><ext-link ext-link-type="uri" xlink:href="http://jmmcr.microbiologyresearch.org">http://jmmcr.microbiologyresearch.org</ext-link></alt-title><alt-title alt-title-type="recto-running-head">PML in a patient with rheumatoid arthritis</alt-title><alt-title alt-title-type="verso-running-head">M. J. A. de Regt and others</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>de Regt</surname><given-names>Marieke J. A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Murk</surname><given-names>Jean-Luc</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schneider-Hohendorf</surname><given-names>Tilman</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wattjes</surname><given-names>Mike P.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoepelman</surname><given-names>Andy I. M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arends</surname><given-names>Joop E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label><sup>1</sup>&#x0200b;</label><institution>Department of Internal Medicine and infectious Diseases, University Medical Centre Utrecht, the Netherlands</institution></aff><aff id="aff2"><label><sup>2</sup>&#x0200b;</label><institution>Department of Medical Microbiology, University Medical Centre Utrecht</institution>, <addr-line>Utrecht</addr-line>, <country> the Netherlands</country></aff><aff id="aff3"><label><sup>3</sup>&#x0200b;</label><institution>Department of Neurology, University of Munster, Munster, Germany</institution></aff><aff id="aff4"><label><sup>4</sup>&#x0200b;</label><institution>Department of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, the Netherlands</institution></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold> Marieke J. A. de Regt <email xlink:href="mjaderegt@gmail.com">mjaderegt@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>8</month><year>2016</year></pub-date><volume>3</volume><issue>4</issue><elocation-id>e005053</elocation-id><history><date date-type="received"><day>20</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="jmmcr-03-5053.pdf"/><abstract><sec><title>Introduction:</title><p>Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating brain infection caused by JC polyomavirus (JCV), primarily seen in patients with severely compromised cellular immunity. Clinical presentation varies depending on the affected white matter. PML prognosis is variable and effective treatments are lacking.</p></sec><sec><title>Case presentation:</title><p>A 75-year-old Chinese woman with type 2 diabetes mellitus, chronic kidney disease and rheumatoid arthritis, treated with low-dose methotrexate and prednisolone for 2.5 years, developed a <italic>Pleurostomophora richardsiae</italic> infection of her left arm. After 6 months of treating this rare black fungus infection with voriconazole, surgery and immunosuppression discontinuation, she presented with progressive afebrile encephalopathy with right-sided hemiparesis. There were no signs of inflammation or metabolic abnormalities. Brain magnetic resonance imaging revealed diffuse frontal white matter lesions and a cerebrospinal fluid PCR confirmed PML due to JC virus. Severe lymphopenia was never present, and at PML diagnosis, CD4 and CD8 T-cell counts were 454 mm<sup>&#x02212;3</sup> and 277 mm<sup>&#x02212;3</sup>. CD8 T-cells were able to respond to JCV VP1 peptide stimulation with TNF&#x003b1; secretion. Peripheral B-cell count was only 8 mm<sup>&#x02212;3</sup>. Mirtazapine and Maraviroc were started, but unfortunately, she rapidly deteriorated and died 5 weeks after PML diagnosis.</p></sec><sec><title>Conclusion:</title><p>Although peripheral lymphocyte counts were never low and CD4 T-cell count was close to normal, the persistent black fungus infection was a hallmark of severely compromised cellular immunity. The unexpected extremely low absolute B-cell count might suggest a protective role for B-cells. The paradoxical, clinical PML onset months after immunosuppressive discontinuation suggests that it was only discovered in the context of an immune reconstitution inflammatory syndrome.</p></sec></abstract><kwd-group><kwd>Progressive multifocal leukoencephalopathy (PML)</kwd><kwd>immune reconstitution inflammatory syndrome (IRIS)</kwd><kwd>rheumatoid arthritis</kwd><kwd>leukoencephalopathy</kwd><kwd>white matter lesions</kwd><kwd>paresis</kwd><kwd>JC-polyomavirus</kwd><kwd>Maraviroc</kwd><kwd>Mirtazapine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OpenAccessEmbargo</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></article-meta><notes><def-list list-type="simple" list-content="abbreviations"><title>Abbreviations:</title><def-item><term>CSF</term><def><p>cerebrospinal fluid</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>IRIS</term><def><p>immune reconstitution inflammatory syndrome</p></def></def-item><def-item><term>JCV</term><def><p>JC polyomavirus</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>MS</term><def><p>multiple sclerosis</p></def></def-item><def-item><term>PML</term><def><p>progressive multifocal leukoencephalopathy</p></def></def-item></def-list></notes></front><body><sec sec-type="intro" id="s1-1"><title>Introduction</title><p>Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating lytic brain infection caused by JC polyomavirus (JCV) (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). Over half of the general population becomes infected with JC virus during life, causing a lifelong asymptomatic infection in various organs, including the bone marrow and kidneys (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). It is only when the cellular immune system becomes severely compromised, mainly due to human immunodeficiency virus (HIV), transplantation or immune modulating monoclonal antibodies (specifically natalizumab), that JCV reactivation causes PML (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). Specific mutations and genomic rearrangements found in JC DNA derived from PML brain tissue are thought to lead to viral tropism for the brain and increased virulence. At what stage JCV crosses the blood&#x02013;brain barrier to infect the brain remains unclear.</p><p>PML has a subacute onset and symptoms are highly variable, depending on the affected white matter. Typical symptoms are cognitive decline, vision loss, impaired speech and paralysis. Signs of inflammation are generally absent (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). Asymptomatic PML has been described in multiple sclerosis (MS) patients (<xref rid="R11" ref-type="bibr">Wattjes <italic>et al.</italic>, 2015</xref>). In general, prognosis of PML is poor depending on the capability of restoring the host immune system (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>).</p><p>In this report, we present a unique case of a patient who developed symptomatic PML months after discontinuation of her rather mild immunosuppressive therapy.</p></sec><sec id="s1-2"><title>Case report</title><p>A 75-year-old Chinese woman with type 2 diabetes mellitus, chronic kidney disease and rheumatoid arthritis received treatment for a rare <italic>Pleurostomophora richardsiae</italic> infection of her left arm. This &#x02018;black fungus&#x02019; was cultured from two separate sterile pus cultures and one wound culture of the left arm and sent to the CBS Fungal Biodiversity Centre and Radboud University Medical Centre for determination. She developed this fungal infection after using methotrexate (7.5 mg weekly) and prednisolone (7.5 mg daily) for 2.5 years. After 6 months of voriconazole, repeated surgical eradication and immunosuppression discontinuation, she presented with fatigue and light-headedness. A week later, she was admitted with progressive weakness, paresis of her right arm and fluctuating apathy. Physical examination demonstrated afebrile encephalopathy with right-sided hemiparesis. A brain magnetic resonance imaging (MRI) was made and a lumbar puncture was performed. Acyclovir was started empirically.</p></sec><sec id="s1-3"><title>Investigations</title><p>Laboratory results showed normal electrolytes, unaltered renal function (creatinine 181 umol l<sup>&#x02212;1</sup>), C-reactive protein 7.1 mg l<sup>&#x02212;1</sup> and leucocyte count 9.4*10E9 l<sup>&#x02212;1</sup>, with normal differentiation. There were no signs of hepatic failure. Brain MRI revealed white matter lesions in both frontal lobes affecting the deep and juxtacortical white matter (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The lesions showed spreading along the white matter tract entering the contralateral hemisphere via the genu anterius of the corpus callosum. A lumbar puncture showed no pleiocytosis (1*106 l<sup>&#x02212;1</sup> leucocytes with no erythrocytes) and only minimally elevated protein (0.51&#x02009;g l<sup>&#x02212;1</sup>) and normal glucose (4.7 mmol l<sup>&#x02212;1</sup>) levels in the cerebrospinal fluid (CSF). HIV, syphilis, borreliosis and toxoplasmosis were ruled out serologically. CSF tested negative by PCR for human herpes viruses and enteroviruses while positive for JCV establishing the diagnosis of PML. Retrospectively performed PCRs on two consecutive blood samples taken 2 months before PML diagnosis were negative for JCV. A urine sample taken 2 weeks after diagnosis showed shedding of JCV in the urine. Peripheral lymphocyte counts were always normal, except during the period of active and still untreated black fungus infection, when they were marginally depressed to levels between 0.46 and 0.75*109 l<sup>&#x02212;1</sup> (<xref ref-type="fig" rid="F2">Fig. 2</xref>). CD4 and CD8&#x02009;T-cell counts at PML diagnosis were 454 mm<sup>&#x02212;3</sup> and 277 mm<sup>&#x02212;3</sup>, respectively, whereas the absolute peripheral B-cell count was only 8 mm<sup>&#x02212;3</sup> (with normal total IgG, IgM and IgA levels). CD8&#x02009;T-cells, isolated at PML diagnosis, reacted to JCV VP1 peptide stimulation with TNF&#x003b1; secretion (<xref ref-type="fig" rid="F3">Fig. 3</xref>). For this assay, a JCV VP1 peptide pool (PepTivator<sup>&#x000ae;</sup>) was purchased from Miltenyi Biotec and used according to the manufacturer&#x02019;s instructions. In brief, thawed peripheral blood mononuclear cell (PBMC) was either rested for 2 h and incubated with 1 &#x000b5;g ml<sup>&#x02212;1</sup> brefeldin A for additional 4 h or stimulated for 6 h with 20 &#x000b5;l of PepTivator<sup>&#x000ae;</sup> stock solution for 5&#x000d7;106 PBMC/ml, as well as addition of 1 &#x000b5;g ml<sup>&#x02212;1</sup> brefeldin A after 2 h. Harvested cells were then stained with fluorochrome-conjugated antibodies against CD3, CD4, CD8 and CD56; fixated and permeabilized and intracellularly stained with a fluorochrome-conjugated antibody against TNF&#x003b1; (Biolegend) as previously described (<xref rid="R3" ref-type="bibr">Breuer <italic>et al.</italic>, 2014</xref>).</p><fig id="F1" fig-type="figure" position="float"><label>Fig. 1.</label><caption><p>MRI brain showing white matter lesions in both frontal lobes affecting the deep and juxtacortical white matter. The lesions show a spreading along the white matter tract entering the contralateral hemisphere via the genu anterius of the corpus callosum.</p></caption><graphic xlink:href="jmmcr-03-5053-f001"/></fig><fig id="F2" fig-type="figure" position="float"><label>Fig. 2.</label><caption><p>Patient&#x02019;s lymphocyte counts over the course of time (denoted by squares). Legend extra symbols: X= negative JCV PCR on blood, L+= positive JCV PCR on CSF (2 log2 copies ml<sup>&#x02212;1</sup>), U+=positive JCV PCR on urine (8 log2 copies ml<sup>&#x02212;1</sup>).
</p></caption><graphic xlink:href="jmmcr-03-5053-f002"/></fig><fig id="F3" fig-type="figure" position="float"><label>Fig. 3.</label><caption><p>CD8 T-cell TNF&#x003b1; secretion after <italic>in vitro</italic> stimulation with JCV VP1 peptide. Circles indicate seven healthy control subjects; triangles indicate the patient&#x02019;s samples. The dotted line indicates the detection threshold. Unstim = TNF&#x003b1; secretion of unstimulated CD8 T-cells; stim = TNF&#x003b1; secretion of CD8 T-cells stimulated with JCV VP1 peptide pool for 6 h.</p></caption><graphic xlink:href="jmmcr-03-5053-f003"/></fig></sec><sec id="s1-4"><title>Diagnosis</title><p>There was a PML due to JC virus reactivation in rheumatoid arthritis patients with severe immunodeficiency.
</p></sec><sec id="s1-5"><title>Treatment</title><p>Mirtazapine was started to block glial cell infection through the serotonin receptor 5HT2a (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>) and, 4 weeks thereafter (when permission for off-label use was received), Maraviroc, a CCR5 antagonist used in HIV, was initiated (<xref rid="R5" ref-type="bibr">Giacomini <italic>et al.</italic>, 2014</xref>).</p></sec><sec id="s1-6"><title>Outcome and follow-up</title><p>Unfortunately, our patient quickly deteriorated due to PML progression, which led to her death 5 weeks after diagnosis and treatment initiation.</p></sec><sec sec-type="discussion" id="s1-7"><title>Discussion</title><p>PML is a rare demyelinating lytic brain infection caused by JCV (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). Over half of the general population becomes infected with JC virus during life, causing a lifelong asymptomatic infection, unless the immune system is severely compromised due to AIDS, transplantation or immune modulating monoclonal antibodies, specifically natalizumab (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). Asymptomatic PML has been described in MS patients (<xref rid="R11" ref-type="bibr">Wattjes <italic>et al.</italic>, 2015</xref>). Only few PML cases have been reported with rheumatoid arthritis (<xref rid="R9" ref-type="bibr">Palazzo &#x00026; Yahia, 2012</xref>). Symptoms have a subacute onset and are highly variable, depending on the affected white matter. Typical symptoms are cognitive decline, vision loss, impaired speech and paralysis. Signs of inflammation are generally absent (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>).</p><p>In retrospect, the persistent black fungus infection in our patient was a hallmark of severely compromised cellular immunity. Surprisingly, peripheral lymphocyte counts were never extremely low and both CD4 and CD8&#x02009;T-cell counts at PML diagnosis were (close to) normal. In addition, CD8&#x02009;T-cells secreted TNF&#x003b1; after stimulation with a JCV VP1 peptide pool. This strongly indicates the presence of JCV-specific lymphocytes, which can be found in the majority of healthy individuals (<xref rid="R10" ref-type="bibr">Du Pasquier <italic>et al.</italic>, 2004</xref>; <xref rid="R1" ref-type="bibr">Koralnik <italic>et al.</italic>, 2001</xref>). The only striking result was an exceptionally low absolute B-cell count (8 mm<sup>&#x02212;3</sup>). Although the role of B-cell depletion in PML pathogenesis is unknown, the increased PML risk in rituximab-treated patients suggests a protective role for B-cells. The paradoxical clinical onset of PML months after immunosuppressives discontinuation and relatively high CD4 count suggests that PML was only discovered in the context of an immune reconstitution inflammatory syndrome (IRIS) (<xref rid="R9" ref-type="bibr">Palazzo &#x00026; Yahia, 2012</xref>), as seen in HIV patients on antiretroviral therapy and in MS patients after natalizumab discontinuation (<xref rid="R9" ref-type="bibr">Palazzo &#x00026; Yahia, 2012</xref>). Only few PML cases have been reported with rheumatoid arthritis (<xref rid="R9" ref-type="bibr">Palazzo &#x00026; Yahia 2012</xref>). Most cases were treated with rituximab and methotrexate and had peripheral lymphopenia. Yet, PML without severe lymphocytopenia has been sparsely reported (<xref rid="R8" ref-type="bibr">Nieuwkamp <italic>et al.</italic>, 2015</xref>; <xref rid="R4" ref-type="bibr">Dammeier <italic>et al.</italic>, 2015</xref>; <xref rid="R2" ref-type="bibr">Hoepner <italic>et al.</italic>, 2015</xref>). Up until now, there has been no specific successful treatment for PML. The most important goal of treatment is to restore immune control over JCV replication by discontinuing immunosuppressives or, in case of HIV, starting antiretroviral therapy. Routine use of corticosteroid therapy in PML IRIS is not recommended, as it may inhibit immune recovery and therefore lead to disease progression (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). Our patient was treated with Mirtazapine to block glial cell infection via the 5HT2a receptor, which has been used with variable success in several studies (<xref rid="R6" ref-type="bibr">Hirsch <italic>et al.</italic>, 2013</xref>). In view of the relatively high levels of (activated) CD4 and CD8&#x02009;T-cell counts, permission for off-label Maraviroc prescription, a CCR5 antagonist used as antiretroviral agent in HIV-infected patients, was requested (<xref rid="R5" ref-type="bibr">Giacomini <italic>et al.</italic>, 2014</xref>). Previously, our group successfully treated three HIV-negative PML patients under the hypothesis that lowering CD4&#x02009;T-cell activation increases its antiviral function (<xref rid="R7" ref-type="bibr">Middel <italic>et al.</italic>, 2015</xref>). Unfortunately, our patient died due to PML progression after only 1 week of Maraviroc therapy (<xref rid="R5" ref-type="bibr">Giacomini <italic>et al.</italic>, 2014</xref>).</p><p>This case report demonstrates that even patients on relatively mild immunosuppressive drugs and no measured severe lymphopenia may have a compromised cellular immunity and therefore are at risk of developing PML. Moreover, in these patients, PML may develop clinically silent, only becoming symptomatic when immune reconstitution has started.</p></sec></body><back><ref-list><title>References</title><ref id="R3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breuer</surname><given-names>J.</given-names></name><name><surname>Schwab</surname><given-names>N.</given-names></name><name><surname>Schneider-Hohendorf</surname><given-names>T.</given-names></name><name><surname>Marziniak</surname><given-names>M.</given-names></name><name><surname>Mohan</surname><given-names>H.</given-names></name><name><surname>Bhatia</surname><given-names>U.</given-names></name><name><surname>Gross</surname><given-names>C. C.</given-names></name><name><surname>Clausen</surname><given-names>B. E.</given-names></name><name><surname>Weishaupt</surname><given-names>C.</given-names></name><etal/></person-group>(<year>2014</year>). <article-title>Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity</article-title>. <source>Ann Neurol</source><volume>75</volume><fpage>739</fpage>&#x02013;<lpage>758</lpage>.<pub-id pub-id-type="doi">10.1002/ana.24165</pub-id><pub-id pub-id-type="pmid">24771567</pub-id></mixed-citation></ref><ref id="R4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dammeier</surname><given-names>N.</given-names></name><name><surname>Schubert</surname><given-names>V.</given-names></name><name><surname>Hauser</surname><given-names>T. K.</given-names></name><name><surname>Bornemann</surname><given-names>A.</given-names></name><name><surname>Bischof</surname><given-names>F.</given-names></name></person-group>(<year>2015</year>). <article-title>Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate</article-title>. <source>BMC Neurol</source><volume>15</volume><fpage>108</fpage>.<pub-id pub-id-type="doi">10.1186/s12883-015-0363-8</pub-id><pub-id pub-id-type="pmid">26152311</pub-id></mixed-citation></ref><ref id="R10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du Pasquier</surname><given-names>R. A.</given-names></name><name><surname>Schmitz</surname><given-names>J. E.</given-names></name><name><surname>Jean-Jacques</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Gordon</surname><given-names>J.</given-names></name><name><surname>Khalili</surname><given-names>K.</given-names></name><name><surname>Letvin</surname><given-names>N. L.</given-names></name><name><surname>Koralnik</surname><given-names>I. J.</given-names></name></person-group>(<year>2004</year>). <article-title>Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals</article-title>. <source>J Virol</source><volume>78</volume><fpage>10206</fpage>&#x02013;<lpage>10210</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.78.18.10206-10210.2004</pub-id><pub-id pub-id-type="pmid">15331755</pub-id></mixed-citation></ref><ref id="R5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacomini</surname><given-names>P. S.</given-names></name><name><surname>Rozenberg</surname><given-names>A.</given-names></name><name><surname>Metz</surname><given-names>I.</given-names></name><name><surname>Araujo</surname><given-names>D.</given-names></name><name><surname>Arbour</surname><given-names>N.</given-names></name><name><surname>Bar-Or</surname><given-names>A.</given-names></name><collab>Maraviroc in Multiple Sclerosis&#x02013;Associated PML&#x02013;IRIS (MIMSAPI) Group</collab></person-group>(<year>2014</year>). <article-title>Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome</article-title>. <source>N Engl J Med</source><volume>370</volume><fpage>486</fpage>&#x02013;<lpage>488</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMc1304828</pub-id><pub-id pub-id-type="pmid">24476450</pub-id></mixed-citation></ref><ref id="R6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>H. H.</given-names></name><name><surname>Kardas</surname><given-names>P.</given-names></name><name><surname>Kranz</surname><given-names>D.</given-names></name><name><surname>Leboeuf</surname><given-names>C.</given-names></name></person-group>(<year>2013</year>). <article-title>The human JC polyomavirus (JCPyV): virological background and clinical implications</article-title>. <source>APMIS</source><volume>121</volume><fpage>685</fpage>&#x02013;<lpage>727</lpage>.<pub-id pub-id-type="doi">10.1111/apm.12128</pub-id><pub-id pub-id-type="pmid">23781977</pub-id></mixed-citation></ref><ref id="R2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoepner</surname><given-names>R.</given-names></name><name><surname>Faissner</surname><given-names>S.</given-names></name><name><surname>Klasing</surname><given-names>A.</given-names></name><name><surname>Schneider</surname><given-names>R.</given-names></name><name><surname>Metz</surname><given-names>I.</given-names></name><name><surname>Bellenberg</surname><given-names>B.</given-names></name><name><surname>Lukas</surname><given-names>C.</given-names></name><name><surname>Altmeyer</surname><given-names>P.</given-names></name><name><surname>Gold</surname><given-names>R.</given-names></name><name><surname>Chan</surname><given-names>A.</given-names></name></person-group>(<year>2015</year>). <article-title>Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source><volume>2</volume>, <elocation-id>e85</elocation-id>.<pub-id pub-id-type="doi">10.1212/NXI.0000000000000085</pub-id><pub-id pub-id-type="pmid">25798449</pub-id></mixed-citation></ref><ref id="R1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koralnik</surname><given-names>I. J.</given-names></name><name><surname>Du Pasquier</surname><given-names>R. A.</given-names></name><name><surname>Letvin</surname><given-names>N. L.</given-names></name></person-group>(<year>2001</year>). <article-title>JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy</article-title>. <source>J Virol</source><volume>75</volume><fpage>3483</fpage>&#x02013;<lpage>3487</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.75.7.3483-3487.2001</pub-id><pub-id pub-id-type="pmid">11238876</pub-id></mixed-citation></ref><ref id="R7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Middel</surname><given-names>A.</given-names></name><name><surname>Arends</surname><given-names>J. E.</given-names></name><name><surname>van Lelyveld</surname><given-names>S. F.</given-names></name><name><surname>Otto</surname><given-names>S.</given-names></name><name><surname>Schuurman</surname><given-names>R.</given-names></name><name><surname>Frijns</surname><given-names>C. J.</given-names></name><name><surname>Tesselaar</surname><given-names>K.</given-names></name><name><surname>Hoepelman</surname><given-names>A. I.</given-names></name></person-group>(<year>2015</year>). <article-title>Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy</article-title>. <source>Neurology</source><volume>85</volume><fpage>104</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.0000000000001713</pub-id><pub-id pub-id-type="pmid">26041329</pub-id></mixed-citation></ref><ref id="R8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwkamp</surname><given-names>D. J.</given-names></name><name><surname>Murk</surname><given-names>J. L.</given-names></name><name><surname>van Oosten</surname><given-names>B. W.</given-names></name><name><surname>Cremers</surname><given-names>C. H.</given-names></name><name><surname>Killestein</surname><given-names>J.</given-names></name><name><surname>Viveen</surname><given-names>M. C.</given-names></name><name><surname>Van Hecke</surname><given-names>W.</given-names></name><name><surname>Frijlink</surname><given-names>D. W.</given-names></name><name><surname>Wattjes</surname><given-names>M. P.</given-names></name><collab>PML in Dutch MS Patients Consortium</collab></person-group>(<year>2015</year>). <article-title>PML in a patient without severe lymphocytopenia receiving dimethyl fumarate</article-title>. <source>N Engl J Med</source><volume>372</volume><fpage>1474</fpage>&#x02013;<lpage>1476</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMc1413724</pub-id><pub-id pub-id-type="pmid">25853764</pub-id></mixed-citation></ref><ref id="R9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palazzo</surname><given-names>E.</given-names></name><name><surname>Yahia</surname><given-names>S. A.</given-names></name></person-group>(<year>2012</year>). <article-title>Progressive multifocal leukoencephalopathy in autoimmune diseases</article-title>. <source>Joint Bone Spine</source><volume>79</volume><fpage>351</fpage>&#x02013;<lpage>355</lpage>.<pub-id pub-id-type="doi">10.1016/j.jbspin.2011.11.002</pub-id><pub-id pub-id-type="pmid">22281228</pub-id></mixed-citation></ref><ref id="R11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wattjes</surname><given-names>M. P.</given-names></name><name><surname>Vennegoor</surname><given-names>A.</given-names></name><name><surname>Steenwijk</surname><given-names>M. D.</given-names></name><name><surname>de Vos</surname><given-names>M.</given-names></name><name><surname>Killestein</surname><given-names>J.</given-names></name><name><surname>van Oosten</surname><given-names>B. W.</given-names></name><name><surname>Mostert</surname><given-names>J.</given-names></name><name><surname>Siepman</surname><given-names>D. A.</given-names></name><name><surname>Moll</surname><given-names>W.</given-names></name><etal/></person-group>(<year>2015</year>). <article-title>MRI pattern in asymptomatic natalizumab- associated PML</article-title>. <source>J Neurol Neurosurg Psychiatry</source><volume>86</volume><fpage>793</fpage>&#x02013;<lpage>798</lpage>.<pub-id pub-id-type="doi">10.1136/jnnp-2014-308630</pub-id><pub-id pub-id-type="pmid">25205744</pub-id></mixed-citation></ref></ref-list></back></article>